Abstract
Summary
Compared with in vitro skin models, ex vivo models can be more accurate on representing the human skin in some case, such as the effect of the extracellular matrix (ECM) in terms of structure, cell signaling mechanisms and the processes of metabolism, the incorporation of skin appendages such as hair follicles and sweat glands, and the effects of dermal absorption. Ex vivo human skin is more appropriate for certain types of research, use of whole skin biopsies in culture allows the effect of individual ingredients and formulations, transdermal delivery, topical penetration and percutaneous absorption to be tested in an environment more closely mimicking normal skin.
The global Ex Vivo Human Skin Models market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Ex Vivo Human Skin Models Industry Forecast” looks at past sales and reviews total world Ex Vivo Human Skin Models sales in 2023, providing a comprehensive analysis by region and market sector of projected Ex Vivo Human Skin Models sales for 2024 through 2030. With Ex Vivo Human Skin Models sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ex Vivo Human Skin Models industry.
This Insight Report provides a comprehensive analysis of the global Ex Vivo Human Skin Models landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ex Vivo Human Skin Models portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ex Vivo Human Skin Models market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ex Vivo Human Skin Models and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ex Vivo Human Skin Models.
United States market for Ex Vivo Human Skin Models is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Ex Vivo Human Skin Models is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Ex Vivo Human Skin Models is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Ex Vivo Human Skin Models players cover Genoskin, MatTek Life Sciences, Creative Bioarray, EpiSkin and Reprocell, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Ex Vivo Human Skin Models market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Products
Customized Testing Services
Segmentation by application
Pharmaceutical
Cosmetic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Genoskin
MatTek Life Sciences
Creative Bioarray
EpiSkin
Reprocell
Alcyomics
Epistem
QIMA Life Sciences
Extherid Biosciences
Perfectus Biomed
Xenometrix
Syntivia
Creative Biolabs
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ex Vivo Human Skin Models market?
What factors are driving Ex Vivo Human Skin Models market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ex Vivo Human Skin Models market opportunities vary by end market size?
How does Ex Vivo Human Skin Models break out type, application?
The global Ex Vivo Human Skin Models market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Ex Vivo Human Skin Models Industry Forecast” looks at past sales and reviews total world Ex Vivo Human Skin Models sales in 2023, providing a comprehensive analysis by region and market sector of projected Ex Vivo Human Skin Models sales for 2024 through 2030. With Ex Vivo Human Skin Models sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ex Vivo Human Skin Models industry.
This Insight Report provides a comprehensive analysis of the global Ex Vivo Human Skin Models landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ex Vivo Human Skin Models portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ex Vivo Human Skin Models market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ex Vivo Human Skin Models and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ex Vivo Human Skin Models.
United States market for Ex Vivo Human Skin Models is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Ex Vivo Human Skin Models is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Ex Vivo Human Skin Models is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Ex Vivo Human Skin Models players cover Genoskin, MatTek Life Sciences, Creative Bioarray, EpiSkin and Reprocell, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Ex Vivo Human Skin Models market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Products
Customized Testing Services
Segmentation by application
Pharmaceutical
Cosmetic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Genoskin
MatTek Life Sciences
Creative Bioarray
EpiSkin
Reprocell
Alcyomics
Epistem
QIMA Life Sciences
Extherid Biosciences
Perfectus Biomed
Xenometrix
Syntivia
Creative Biolabs
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ex Vivo Human Skin Models market?
What factors are driving Ex Vivo Human Skin Models market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ex Vivo Human Skin Models market opportunities vary by end market size?
How does Ex Vivo Human Skin Models break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ex Vivo Human Skin Models Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ex Vivo Human Skin Models by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ex Vivo Human Skin Models by Country/Region, 2019, 2023 & 2030
2.2 Ex Vivo Human Skin Models Segment by Type
2.2.1 Products
2.2.2 Customized Testing Services
2.3 Ex Vivo Human Skin Models Sales by Type
2.3.1 Global Ex Vivo Human Skin Models Sales Market Share by Type (2019-2024)
2.3.2 Global Ex Vivo Human Skin Models Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ex Vivo Human Skin Models Sale Price by Type (2019-2024)
2.4 Ex Vivo Human Skin Models Segment by Application
2.4.1 Pharmaceutical
2.4.2 Cosmetic
2.4.3 Others
2.5 Ex Vivo Human Skin Models Sales by Application
2.5.1 Global Ex Vivo Human Skin Models Sale Market Share by Application (2019-2024)
2.5.2 Global Ex Vivo Human Skin Models Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ex Vivo Human Skin Models Sale Price by Application (2019-2024)
3 Global Ex Vivo Human Skin Models by Company
3.1 Global Ex Vivo Human Skin Models Breakdown Data by Company
3.1.1 Global Ex Vivo Human Skin Models Annual Sales by Company (2019-2024)
3.1.2 Global Ex Vivo Human Skin Models Sales Market Share by Company (2019-2024)
3.2 Global Ex Vivo Human Skin Models Annual Revenue by Company (2019-2024)
3.2.1 Global Ex Vivo Human Skin Models Revenue by Company (2019-2024)
3.2.2 Global Ex Vivo Human Skin Models Revenue Market Share by Company (2019-2024)
3.3 Global Ex Vivo Human Skin Models Sale Price by Company
3.4 Key Manufacturers Ex Vivo Human Skin Models Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ex Vivo Human Skin Models Product Location Distribution
3.4.2 Players Ex Vivo Human Skin Models Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Ex Vivo Human Skin Models by Geographic Region
4.1 World Historic Ex Vivo Human Skin Models Market Size by Geographic Region (2019-2024)
4.1.1 Global Ex Vivo Human Skin Models Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ex Vivo Human Skin Models Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ex Vivo Human Skin Models Market Size by Country/Region (2019-2024)
4.2.1 Global Ex Vivo Human Skin Models Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ex Vivo Human Skin Models Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ex Vivo Human Skin Models Sales Growth
4.4 APAC Ex Vivo Human Skin Models Sales Growth
4.5 Europe Ex Vivo Human Skin Models Sales Growth
4.6 Middle East & Africa Ex Vivo Human Skin Models Sales Growth
5 Americas
5.1 Americas Ex Vivo Human Skin Models Sales by Country
5.1.1 Americas Ex Vivo Human Skin Models Sales by Country (2019-2024)
5.1.2 Americas Ex Vivo Human Skin Models Revenue by Country (2019-2024)
5.2 Americas Ex Vivo Human Skin Models Sales by Type
5.3 Americas Ex Vivo Human Skin Models Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ex Vivo Human Skin Models Sales by Region
6.1.1 APAC Ex Vivo Human Skin Models Sales by Region (2019-2024)
6.1.2 APAC Ex Vivo Human Skin Models Revenue by Region (2019-2024)
6.2 APAC Ex Vivo Human Skin Models Sales by Type
6.3 APAC Ex Vivo Human Skin Models Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ex Vivo Human Skin Models by Country
7.1.1 Europe Ex Vivo Human Skin Models Sales by Country (2019-2024)
7.1.2 Europe Ex Vivo Human Skin Models Revenue by Country (2019-2024)
7.2 Europe Ex Vivo Human Skin Models Sales by Type
7.3 Europe Ex Vivo Human Skin Models Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ex Vivo Human Skin Models by Country
8.1.1 Middle East & Africa Ex Vivo Human Skin Models Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ex Vivo Human Skin Models Revenue by Country (2019-2024)
8.2 Middle East & Africa Ex Vivo Human Skin Models Sales by Type
8.3 Middle East & Africa Ex Vivo Human Skin Models Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ex Vivo Human Skin Models
10.3 Manufacturing Process Analysis of Ex Vivo Human Skin Models
10.4 Industry Chain Structure of Ex Vivo Human Skin Models
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ex Vivo Human Skin Models Distributors
11.3 Ex Vivo Human Skin Models Customer
12 World Forecast Review for Ex Vivo Human Skin Models by Geographic Region
12.1 Global Ex Vivo Human Skin Models Market Size Forecast by Region
12.1.1 Global Ex Vivo Human Skin Models Forecast by Region (2025-2030)
12.1.2 Global Ex Vivo Human Skin Models Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Ex Vivo Human Skin Models Forecast by Type
12.7 Global Ex Vivo Human Skin Models Forecast by Application
13 Key Players Analysis
13.1 Genoskin
13.1.1 Genoskin Company Information
13.1.2 Genoskin Ex Vivo Human Skin Models Product Portfolios and Specifications
13.1.3 Genoskin Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Genoskin Main Business Overview
13.1.5 Genoskin Latest Developments
13.2 MatTek Life Sciences
13.2.1 MatTek Life Sciences Company Information
13.2.2 MatTek Life Sciences Ex Vivo Human Skin Models Product Portfolios and Specifications
13.2.3 MatTek Life Sciences Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 MatTek Life Sciences Main Business Overview
13.2.5 MatTek Life Sciences Latest Developments
13.3 Creative Bioarray
13.3.1 Creative Bioarray Company Information
13.3.2 Creative Bioarray Ex Vivo Human Skin Models Product Portfolios and Specifications
13.3.3 Creative Bioarray Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Creative Bioarray Main Business Overview
13.3.5 Creative Bioarray Latest Developments
13.4 EpiSkin
13.4.1 EpiSkin Company Information
13.4.2 EpiSkin Ex Vivo Human Skin Models Product Portfolios and Specifications
13.4.3 EpiSkin Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 EpiSkin Main Business Overview
13.4.5 EpiSkin Latest Developments
13.5 Reprocell
13.5.1 Reprocell Company Information
13.5.2 Reprocell Ex Vivo Human Skin Models Product Portfolios and Specifications
13.5.3 Reprocell Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Reprocell Main Business Overview
13.5.5 Reprocell Latest Developments
13.6 Alcyomics
13.6.1 Alcyomics Company Information
13.6.2 Alcyomics Ex Vivo Human Skin Models Product Portfolios and Specifications
13.6.3 Alcyomics Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Alcyomics Main Business Overview
13.6.5 Alcyomics Latest Developments
13.7 Epistem
13.7.1 Epistem Company Information
13.7.2 Epistem Ex Vivo Human Skin Models Product Portfolios and Specifications
13.7.3 Epistem Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Epistem Main Business Overview
13.7.5 Epistem Latest Developments
13.8 QIMA Life Sciences
13.8.1 QIMA Life Sciences Company Information
13.8.2 QIMA Life Sciences Ex Vivo Human Skin Models Product Portfolios and Specifications
13.8.3 QIMA Life Sciences Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 QIMA Life Sciences Main Business Overview
13.8.5 QIMA Life Sciences Latest Developments
13.9 Extherid Biosciences
13.9.1 Extherid Biosciences Company Information
13.9.2 Extherid Biosciences Ex Vivo Human Skin Models Product Portfolios and Specifications
13.9.3 Extherid Biosciences Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Extherid Biosciences Main Business Overview
13.9.5 Extherid Biosciences Latest Developments
13.10 Perfectus Biomed
13.10.1 Perfectus Biomed Company Information
13.10.2 Perfectus Biomed Ex Vivo Human Skin Models Product Portfolios and Specifications
13.10.3 Perfectus Biomed Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Perfectus Biomed Main Business Overview
13.10.5 Perfectus Biomed Latest Developments
13.11 Xenometrix
13.11.1 Xenometrix Company Information
13.11.2 Xenometrix Ex Vivo Human Skin Models Product Portfolios and Specifications
13.11.3 Xenometrix Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Xenometrix Main Business Overview
13.11.5 Xenometrix Latest Developments
13.12 Syntivia
13.12.1 Syntivia Company Information
13.12.2 Syntivia Ex Vivo Human Skin Models Product Portfolios and Specifications
13.12.3 Syntivia Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Syntivia Main Business Overview
13.12.5 Syntivia Latest Developments
13.13 Creative Biolabs
13.13.1 Creative Biolabs Company Information
13.13.2 Creative Biolabs Ex Vivo Human Skin Models Product Portfolios and Specifications
13.13.3 Creative Biolabs Ex Vivo Human Skin Models Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Creative Biolabs Main Business Overview
13.13.5 Creative Biolabs Latest Developments
14 Research Findings and Conclusion